Ohno R, Hirano M, Imai K, Koie K, Kamiya T, Nishiwaki H, Ishiguro J, Uetani T, Sako F, Imamura K
First Department of Internal Medicine, Nagoya University School of Medicine, Nagoya, Japan.
Cancer. 1975 Dec;36(6):1945-9. doi: 10.1002/cncr.2820360903.
Thirty-seven adults with acute myelogenous leukemia (AML) were treated with a combination of daunorubicin, cytosine arabinoside, 6-mercaptopurine riboside, and prednisolone (DCMP) for remission induction. Twenty-three of 37 patients (62.2%) achieved complete remission, three, partial remission and 11, failure. Patients with prior therapy responded as well as patients without it. The median survival time of the patients who received DCMP for their initial remission induction therapy was 10.3 months and that of the patients who obtained complete remission was 17 months. Complete remission occurred in 21 out of 28 patients (75%) less than 40 years old but in only two out of nine patients (22.2%) more than 40 years old. The most common toxic effects were severe myelosuppression and liver function abnormalities. DCMP therapy is an effective remission induction chemotherapy for adults with AML.
37例急性髓性白血病（AML）成人患者接受柔红霉素、阿糖胞苷、6-巯基嘌呤核苷和泼尼松龙（DCMP）联合治疗以诱导缓解。37例患者中有23例（62.2%）达到完全缓解，3例部分缓解，11例治疗失败。接受过先前治疗的患者与未接受过先前治疗的患者反应相同。接受DCMP进行初始缓解诱导治疗的患者中位生存时间为10.3个月，达到完全缓解的患者中位生存时间为17个月。28例年龄小于40岁的患者中有21例（75%）达到完全缓解，但9例年龄大于40岁的患者中只有2例（22.2%）达到完全缓解。最常见的毒性作用是严重的骨髓抑制和肝功能异常。DCMP疗法是成人AML有效的缓解诱导化疗方法。
